LCM
FULC icon

Laurion Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Laurion Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-144,721
Closed -$1.37M – 632
2024
Q1 		$1.37M Hold
144,721
– – 0.01% 358
2023
Q4 		$977K Buy
+144,721
New +$642K 0.01% 342
2023
Q3 		– Sell
-33,645
Closed -$111K – 548
2023
Q2 		$111K Buy
+33,645
New +$98.9K ﹤0.01% 515
2020
Q1 		– Sell
-33,552
Closed -$558K – 873
2019
Q4 		$558K Sell
33,552
-61,200
-65% -$585K ﹤0.01% 675
2019
Q3 		$629K Buy
+94,752
New +$1.05M ﹤0.01% 725

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Laurion Capital Management's FULC Position: Q2 2024 in Review

Laurion Capital Management sold out of Fulcrum Therapeutics (FULC) in Q2 2024, closing a stake of 144,721 shares — an estimated $1.37M sold.

Laurion Capital Management first reported a position in FULC in Q3 2019 and held it in 5 quarters. The position peaked at $1.37M in Q1 2024. 121 funds tracked by Wall St. Rank hold FULC as of Q2 2024.

  • Laurion Capital Management reported no remaining Fulcrum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 144,721 Fulcrum Therapeutics shares in Q2 2024, an estimated $1.37M.
  • Laurion Capital Management first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 5 quarters.
  • Laurion Capital Management's Fulcrum Therapeutics position peaked at $1.37M in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.